<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-id journal-id-type="nlm-ta">Eur J Cardiovasc Prev Rehabil</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826711426091</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826711426091</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Risk factors</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific papers</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Prognostic significance of serial Q/ST-T changes by the Minnesota Code and Novacode in the Atherosclerosis Risk in Communities (ARIC) study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhang</surname><given-names>Zhu-ming</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711426091">1</xref>
<xref ref-type="corresp" rid="corresp1-1741826711426091"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Prineas</surname><given-names>Ronald J</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711426091">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Soliman</surname><given-names>Elsayed Z</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711426091">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Baggett</surname><given-names>Chris</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711426091">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Heiss</surname><given-names>Gerardo</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711426091">2</xref>
</contrib>
<contrib contrib-type="author">
<collab>(for the ARIC Research Group)</collab>
</contrib>
</contrib-group>
<aff id="aff1-1741826711426091"><label>1</label>Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.</aff>
<aff id="aff2-1741826711426091"><label>2</label>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</aff>
<author-notes>
<corresp id="corresp1-1741826711426091">Zhu-ming Zhang, Division of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, North Carolina 27157, USA Email: <email>zmzhang@wfubmc.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>6</issue>
<fpage>1430</fpage>
<lpage>1436</lpage>
<history>
<date date-type="received"><day>21</day><month>7</month><year>2011</year></date>
<date date-type="accepted"><day>19</day><month>9</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p><bold>Aims:</bold> To compare the value of serial electrocardiographic (ECG) changes by the two most widely used ECG classification systems–the Minnesota Code (MC) and Novacode (Nova) for the prediction of subsequent coronary heart disease (CHD) and total mortality.</p>
<p><bold>Methods and results:</bold> We studied 12-lead ECGs from 12,477 participants (average age 54 years at baseline; 58% women; 76% non-Hispanic white) in the Atherosclerosis Risk in Communities (ARIC) Study, who were free of CHD at baseline in 1987, had both good-quality ECGs at baseline and at first study-scheduled follow-up visit, and had ECG QRS duration &lt;120 ms. A total 2119 participants died (17%), including 280 CHD deaths during an average 17-year follow up. Cox regression models assessed outcome associated with significant serial ECG changes by MC and Nova separately. For CHD death the hazard ratio was 6.8 (95% CI 3.5–13.3) for incident Nova myocardial infarction (MI), and 5.7 (95% CI 2.7–11.9) for MC-MI in a multivariable model adjusted for clinical and demographic characteristics, and ECG left ventricular hypertrophy. The increased risk for total mortality doubled for both Nova and MC serial ECG MI. Major evolving ST-T wave abnormalities alone were associated with a ≥132% increased risk for CHD death and a 50% increased risk for total mortality by either Nova or MC.</p>
<p><bold>Conclusion:</bold> ECG serial change by both MC and Nova are equally valuable predictors for future fatal cardiac events and total mortality and hence equally useful prognostic indicators in clinical trials and epidemiological studies.</p>
</abstract>
<kwd-group>
<kwd>Cardiovascular disease</kwd>
<kwd>electrocardiography</kwd>
<kwd>Minnesota Code</kwd>
<kwd>mortality</kwd>
<kwd>Novacode</kwd>
<kwd>serial change</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826711426091" sec-type="intro"><title>Introduction</title>
<p>Well-defined criteria for clinically significant evolution of electrocardiographic (ECG) abnormalities are frequently called for.<sup><xref ref-type="bibr" rid="bibr1-1741826711426091">1</xref>–<xref ref-type="bibr" rid="bibr4-1741826711426091">4</xref></sup> The Minnesota Code (MC) was originally developed to determine cardiac-related disease prevalence in population studies in the early 1960s.<sup><xref ref-type="bibr" rid="bibr5-1741826711426091">5</xref></sup> Later, criteria were developed to document incident events using objective side-by-side ECG comparison rules.<sup><xref ref-type="bibr" rid="bibr6-1741826711426091">6</xref>,<xref ref-type="bibr" rid="bibr7-1741826711426091">7</xref></sup> The Novacode (Nova) is an extension of the MC,<sup><xref ref-type="bibr" rid="bibr8-1741826711426091">8</xref>,<xref ref-type="bibr" rid="bibr9-1741826711426091">9</xref></sup> which provides a comprehensive hierarchical set of criteria for both prevalent ECG abnormalities and clinically significant serial ECG changes. Both systems have been used in many epidemiological studies and clinical trials. We have previously compared MC and Nova in terms of their ability to detect prevalent ECG abnormalities in men and women separately and how these ECG abnormalities are predictive of future cardiovascular disease (CVD) events.<sup><xref ref-type="bibr" rid="bibr10-1741826711426091">10</xref>,<xref ref-type="bibr" rid="bibr11-1741826711426091">11</xref></sup> In the present study, we compared the value of serial ECG changes as detected by MC and Nova to predict subsequent incident fatal cardiac events and total mortality.</p>
</sec>
<sec id="sec2-1741826711426091" sec-type="methods"><title>Methods</title>
<sec id="sec3-1741826711426091"><title>Study population</title>
<p>The Atherosclerosis Risk In Communities (ARIC) Study, is a population-based, multicentre prospective study to investigate the natural history and aetiology of atherosclerotic and CVD events from four US communities in Maryland, Minnesota, Mississippi, and North Carolina (<italic>n</italic> = 15,792 men and women aged 45–64 years at enrolment). Participants were interviewed at home, and invited to a baseline clinical examination (1987–89). They attended three further clinical examinations at approximately 3-year intervals, and received a follow-up telephone call yearly. Details of study design, protocol, sampling procedures, and selection and exclusion criteria have been published.<sup><xref ref-type="bibr" rid="bibr12-1741826711426091">12</xref></sup> After excluding the participants with prevalent coronary heart disease (CHD) [ECG evidence or a history of myocardial infarction (MI)], angina, coronary artery bypass surgery, coronary angioplasty, or congestive heart failure at baseline, we only focused on those participants who had both good-quality ECGs at baseline and at first study-scheduled follow-up visit (at year 4), and had ECG QRS duration &lt;120 ms. There remained 12,477 participants for the present study (Supplementary Figure 1, available online).</p>
</sec>
<sec id="sec4-1741826711426091"><title>Outcome ascertainment</title>
<p>Relevant outcomes were incident CHD deaths and all-cause mortality. Deaths and hospitalization events were ascertained using annual follow-up calls to the cohort members, review of vital records, and community surveillance of hospitalized and fatal events. A CHD death was defined as lacking a probable non-CHD cause, and occurring in the context of a recent MI, chest pain within 72 hours of death, or a history of CHD occurring from the first triennial follow-up visit to 31 December 2006 with an average 17-year follow up. Events were classified independently by a separate committee. Detailed definitions for the diagnosis of acute MI and death due to CHD have been published.<sup><xref ref-type="bibr" rid="bibr13-1741826711426091">13</xref>,<xref ref-type="bibr" rid="bibr14-1741826711426091">14</xref></sup></p>
</sec>
<sec id="sec5-1741826711426091"><title>ECG methodology</title>
<p>Identical electrocardiographs (MAC PC; Marquette Electronics Inc., Milwaukee, Wisconsin, USA) were used in all clinic sites, and resting 10-second standard simultaneous 12-lead ECGs were recorded in all participants using strictly standardized procedures. The chest electrodes were located in precise positions. All ECGs were processed in a central ECG laboratory (EPICORE Center, University of Alberta, Edmonton, Canada, and later at EPICARE Center, Wake Forest University, Winston-Salem, USA), where they were visually inspected for technical errors and inadequate quality. The ECGs first processed by the Dalhousie ECG program were repeated for the present study using the 2001 version of the GE Marquette 12SL program (Marquette 12SL ECG Physician Guide available at <ext-link ext-link-type="uri" xlink:href="www.ge-healthcare.com">www.ge-healthcare.com</ext-link>). ECGs were classified according to the Nova and MC using variables derived from the median complex of the Marquette measurement matrix.</p>
</sec>
<sec id="sec6-1741826711426091"><title>ECG serial classification criteria for incident MI/ischaemia</title>
<p>Serial change Nova classification of incident MI/ischaemia is based on the change of a score in the appearance of the duration and/or voltage of the Q-wave exceeding specified limits and on whether an ST-segment and T-wave abnormality have evolved significantly from the reference ECG.<sup><xref ref-type="bibr" rid="bibr7-1741826711426091">7</xref>,<xref ref-type="bibr" rid="bibr9-1741826711426091">9</xref></sup> Nova classifies incident MI/ischaemia as I-Nova-5 (I for ‘incident’) with eight hierarchies: incident Nova-MI was identified by I-Nova-5.1 to I-Nova-5.4, and I-Nova-5.5/5.6 was for isolated incident ECG ischaemia by Nova (<xref ref-type="table" rid="table1-1741826711426091">Table 1</xref> and Supplementary <xref ref-type="table" rid="table1-1741826711426091">Table 1</xref>).
<table-wrap id="table1-1741826711426091" position="float"><label>Table 1.</label><caption><p>ECG serial change criteria for incident myocardial infarction and ischaemia by the Novacode (Nova) and the Minnesota Code (MC)</p></caption>
<graphic alternate-form-of="table1-1741826711426091" xlink:href="10.1177_1741826711426091-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Category</th>
<th>Novacode</th>
<th colspan="2">Minnesota Code</th></tr></thead>
<tbody align="left">
<tr>
<td colspan="4">Evolving Q-wave</td></tr>
<tr>
<td> Major Q-wave evolution</td>
<td>I-Nova-5.1</td>
<td>I-MC-C.1</td>
<td>Q1</td></tr>
<tr>
<td> Moderate Q-wave evolution with evolving ST-T</td>
<td>I-Nova-5.2</td>
<td>I-MC-C.2</td>
<td>Q2, Q3, Q4</td></tr>
<tr>
<td> Moderate Q-wave evolution with nonevolving ST-T</td>
<td>I-Nova-5.3</td>
<td>I-MC-C.3</td>
<td>N/A</td></tr>
<tr>
<td> Borderline Q-wave evolution with evolving ST-T</td>
<td>I-Nova-5.4</td>
<td>I-MC-C.4</td>
<td>Q5, Q6, Q7</td></tr>
<tr>
<td colspan="4">Evolving ST-T change</td></tr>
<tr>
<td> Profound ST-T evolution without evolving Q-waves</td>
<td>I-Nova-5.5</td>
<td>I-MC-C.5</td>
<td>ST-T1, ST-T3, STE-1</td></tr>
<tr>
<td> Evolving ST-T with nonevolving Q-waves</td>
<td>I-Nova-5.6.1</td>
<td>I-MC-C.6</td>
<td>ST-T2, ST-T4</td></tr>
<tr>
<td> Isolated ST-T evolution</td>
<td>I-Nova-5.6.2</td>
<td>I-MC-C.6</td>
<td>ST-T5, ST-T6, ST-T7</td></tr>
<tr>
<td colspan="4">Borderline Q-wave change</td></tr>
<tr>
<td> Borderline Q-wave evolution with nonevolving ST-T</td>
<td>I-Nova-5.7</td>
<td>I-MC-C.7</td>
<td>Q8</td></tr>
<tr>
<td>No significant Q or ST-T evolution</td>
<td/>
<td/>
<td/></tr>
<tr>
<td> No significant Q-wave or ST-T evolution</td>
<td>I-Nova-5.0</td>
<td>I-MC-C.0</td>
<td>Q0</td></tr>
<tr>
<td colspan="4">New incident myocardial infarction/ischaemia</td></tr>
<tr>
<td rowspan="2"> New incident myocardial infarction</td>
<td>I-Nova-5.1 to</td>
<td>I-MC-C.1 to</td>
<td>Q1 to Q7</td></tr>
<tr>
<td>I-Nova-5.4</td>
<td>I-MC-C.4</td>
<td/></tr>
<tr>
<td> New isolated major ischaemia</td>
<td>I-Nova-5.5/5.6</td>
<td>I-MC-C.5/C.6</td>
<td>ST-T1 to ST-T7, STE-1</td></tr>
<tr>
<td rowspan="2"> Any new Q/ST-T change</td>
<td>I-Nova-5.1 to</td>
<td>I-MC-C.1 to</td>
<td>Q1 to Q7 or</td></tr>
<tr>
<td>I-Nova-5.7</td>
<td>I-MC-C.7</td>
<td>ST-T1 to ST-T7, STE-1</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826711426091"><p>Minnesota Code includes evolving Q/ST code and combined MC serial change code (I-MC-C.X). See Supplementary <xref ref-type="table" rid="table1-1741826711426091">Table 1</xref> and <xref ref-type="table" rid="table2-1741826711426091">2</xref> and references<sup>7</sup> and <sup>9</sup>.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>MC for classification of incident MI/ischaemia incorporates four MC codes: code 1 for Q and QS patterns, code 4 for ST-segment depression, code 5 for T-wave negativity, and code 9–2 for ST-segment elevation. All serial changes were confirmed by side-by-side ECG comparison of Q and ST-T change between the first and subsequent examinations. Serial change MC categorizes evolving Q codes as Q1 to Q8, and for evolving ST-T codes as STE-1, ST-T1 to ST-T7.<sup><xref ref-type="bibr" rid="bibr5-1741826711426091">5</xref>–<xref ref-type="bibr" rid="bibr7-1741826711426091">7</xref></sup> Additionally, in order to achieve equivalency with the I-Nova-5 code, eight hierarchic levels from I-MC-C.1 to I-MC-C.7 were combined (<xref ref-type="table" rid="table1-1741826711426091">Table 1</xref> and Supplementary <xref ref-type="table" rid="table2-1741826711426091">Table 2</xref>). Incident MC-MI was identified either by Q1 to Q7, or I-MC-C.1 to I-MC-C.4, and I-MC-C5/C.6 was for isolated incident ECG ischaemia by MC.
<table-wrap id="table2-1741826711426091" position="float"><label>Table 2.</label><caption><p>Characteristics of study participants including the outcomes during average 17-year follow up</p></caption>
<graphic alternate-form-of="table2-1741826711426091" xlink:href="10.1177_1741826711426091-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristics</th>
<th>Population (<italic>n</italic> = 12,477)</th></tr></thead>
<tbody align="left">
<tr>
<td colspan="2">Baseline</td></tr>
<tr>
<td> Age (year)</td>
<td>54 ± 6</td></tr>
<tr>
<td> Body mass index (kg/m<sup>2</sup>)</td>
<td>28 ± 5</td></tr>
<tr>
<td> Systolic blood pressure (mmHg)</td>
<td>120 ± 18</td></tr>
<tr>
<td> Diastolic blood pressure (mmHg)</td>
<td>73 ± 11</td></tr>
<tr>
<td> Women</td>
<td>7248 (58.09)</td></tr>
<tr>
<td> African-American</td>
<td>3048 (24.43)</td></tr>
<tr>
<td> Current smoking</td>
<td>3321 (26.66)</td></tr>
<tr>
<td> Hypertension</td>
<td>4001 (32.20)</td></tr>
<tr>
<td> Diabetes mellitus</td>
<td>1259 (10.17)</td></tr>
<tr>
<td> LVH by Nova or MC</td>
<td>650 (5.21)</td></tr>
<tr>
<td> CHD death<sup><xref ref-type="table-fn" rid="table-fn2-1741826711426091">a</xref></sup></td>
<td>280 (2.24)</td></tr>
<tr>
<td> Total mortality<sup><xref ref-type="table-fn" rid="table-fn2-1741826711426091">a</xref></sup></td>
<td>2119 (16.98)</td></tr>
<tr>
<td colspan="2"> ECG ischaemia by Nova<sup><xref ref-type="table-fn" rid="table-fn2-1741826711426091">b</xref></sup></td></tr>
<tr>
<td>  Nova-5.5</td>
<td>194 (1.55)</td></tr>
<tr>
<td>  Nova-5.6</td>
<td>254 (2.04)</td></tr>
<tr>
<td>  Nova-5.7</td>
<td>509 (4.08)</td></tr>
<tr>
<td>  Nova-5.8</td>
<td>2043 (16.37)</td></tr>
<tr>
<td>  Nova-5.0</td>
<td>9477 (75.96)</td></tr>
<tr>
<td colspan="2"> ECG ischaemia by combined MC<sup><xref ref-type="table-fn" rid="table-fn2-1741826711426091">b</xref></sup></td></tr>
<tr>
<td>  MC-C.5</td>
<td>133 (1.07)</td></tr>
<tr>
<td>  MC-C.6</td>
<td>343 (2.75)</td></tr>
<tr>
<td>  MC-C.7</td>
<td>644 (5.16)</td></tr>
<tr>
<td>  MC-C.8</td>
<td>1188 (9.52)</td></tr>
<tr>
<td>  MC-C.0</td>
<td>10,169 (81.50)</td></tr>
<tr>
<td colspan="2">ECG serial change for MI/ischaemia by Nova/MC at first scheduled follow-up visit</td></tr>
<tr>
<td colspan="2"> ECG serial change by MC</td></tr>
<tr>
<td>  Q1</td>
<td>44 (0.35)</td></tr>
<tr>
<td>  Q2</td>
<td>1 (0.01)</td></tr>
<tr>
<td>  Q3</td>
<td>0</td></tr>
<tr>
<td>  Q4</td>
<td>0</td></tr>
<tr>
<td>  Q5</td>
<td>1 (0.01)</td></tr>
<tr>
<td>  Q6</td>
<td>3 (0.02)</td></tr>
<tr>
<td>  Q7</td>
<td>0</td></tr>
<tr>
<td>  Q8</td>
<td>416 (3.33)</td></tr>
<tr>
<td>  Q0</td>
<td>11,460 (91.85)</td></tr>
<tr>
<td>  STE-1</td>
<td>17 (0.14)</td></tr>
<tr>
<td>  ST-T1</td>
<td>81 (0.65)</td></tr>
<tr>
<td>  ST-T2</td>
<td>2 (0.02)</td></tr>
<tr>
<td>  ST-T3</td>
<td>247 (1.98)</td></tr>
<tr>
<td>  ST-T4</td>
<td>2 (0.02)</td></tr>
<tr>
<td>  ST-T5</td>
<td>5 (0.04)</td></tr>
<tr>
<td>  ST-T6</td>
<td>3 (0.02)</td></tr>
<tr>
<td>  ST-T7</td>
<td>195 (1.56)</td></tr>
<tr>
<td colspan="2"> ECG serial change by Nova</td></tr>
<tr>
<td>  I-Nova-5.1</td>
<td>11 (0.09)</td></tr>
<tr>
<td>  I-Nova-5.2</td>
<td>9 (0.07)</td></tr>
<tr>
<td>  I-Nova-5.3</td>
<td>22 (0.18)</td></tr>
<tr>
<td>  I-Nova-5.4</td>
<td>12 (0.10)</td></tr>
<tr>
<td>  I-Nova-5.5</td>
<td>48 (0.38)</td></tr>
<tr>
<td>  I-Nova-5.6</td>
<td>169 (1.35)</td></tr>
<tr>
<td>  I-Nova-5.7</td>
<td>228 (1.83)</td></tr>
<tr>
<td>  I-Nova-5.0</td>
<td>11,978 (96.0)</td></tr>
<tr>
<td colspan="2"> ECG serial change by combined MC</td></tr>
<tr>
<td>  I-MC-C.1</td>
<td>44 (0.35)</td></tr>
<tr>
<td>  I-MC-C.2</td>
<td>1 (0.01)</td></tr>
<tr>
<td>  I-MC-C.3</td>
<td>N/A</td></tr>
<tr>
<td>  I-MC-C.4</td>
<td>4 (0.03)</td></tr>
<tr>
<td>  I-MC-C.5</td>
<td>328 (2.63)</td></tr>
<tr>
<td>  I-MC-C.6</td>
<td>224 (1.80)</td></tr>
<tr>
<td>  I-MC-C.7</td>
<td>416 (3.33)</td></tr>
<tr>
<td>  I-MC-C.0</td>
<td>11,460 (91.85)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1741826711426091"><p>Values are mean ± SD or <italic>n</italic> (%). See <xref ref-type="table" rid="table1-1741826711426091">Table 1</xref> for serial change criteria. <sup>a</sup>Outcomes CHD death and total mortality during first scheduled follow-up visit to average 17-year follow up. <sup>b</sup>See reference 11. ECG-LVH, left ventricular hypertrophy by Cornell voltage or MC 3.1; MC, Minnesota Code; Nova, Novacode.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>One difference between the Nova and MC is that Q-wave smaller than 100 µV are ignored in the MC, whereas Nova scores Q-waves that are at least 20 ms in duration and 75 µV in amplitude.</p>
</sec>
<sec id="sec7-1741826711426091"><title>Statistical analysis</title>
<p>Frequency distributions of all ECG and non-ECG variables were first inspected to rule out anomalies and outliers possibly due to measurement artefacts. Descriptive statistics were used to determine mean, standard deviations, and percentiles for continuous variables, and frequencies and percentages for categorical variables. Cox’s proportional hazards analysis was used to assess the effects of serial change ECG variables on the risk of CHD death and total mortality, and comparison of MC or Nova predictors. Univariate and multivariate models were used in the analysis. Multivariate mode adjusted for the key demographic and clinical characteristics which included education, smoking status, alcohol use, hypertension, diabetes mellitus, history of cancer, body mass index, systolic blood pressure, white blood cell, high-density lipoprotein, low-density lipoprotein, baseline glucose, insulin, fibrinogen, uric acid, creatinine, geographic regions, and ECG left ventricular hypertrophy (ECG-LVH) by MC/Nova – all defined in previous reports.<sup><xref ref-type="bibr" rid="bibr7-1741826711426091">7</xref>,<xref ref-type="bibr" rid="bibr12-1741826711426091">12</xref>–<xref ref-type="bibr" rid="bibr14-1741826711426091">14</xref></sup> Analyses were performed with SAS version 9.1.3 (SAS Institute, Cary, North Carolina, USA).</p>
</sec>
</sec>
<sec id="sec8-1741826711426091" sec-type="results"><title>Results</title>
<p>Among 12,477 participants with ECGs both at baseline and at first triennial visit, the mean age at baseline was 54 years and there were 58% women and 76% non-Hispanic white. Of these, 32% had hypertension, 10% diabetes, and 5% major ECG ST-T abnormalities by either Nova or MC (3.6% by Nova and 3.8% by MC). During an average 17-year post-first follow-up visit, total mortality was 17.0% (2119) and CHD death was 2.2% (280) (<xref ref-type="table" rid="table2-1741826711426091">Table 2</xref>).</p>
<p><xref ref-type="table" rid="table2-1741826711426091">Table 2</xref> shows 0.44% (54) patients had new incident ECG MI by Nova (I-Nova-5.1 to I-Nova-5.4) and 0.39% (49) patients by MC (I-MC-C.1 to I-MC-C.4) at first follow-up visit. Furthermore, 4.0% (499) patients had any new Q/ST-T change by Nova (i.e. codes I-Nova-5.1 through I-Nova-5.7), and 8.2% (1017) patients had new codable MC serial change (codes I-MC-C.1 through I-MC-C.7). The agreement coefficient by Kappa for new incident MI by Nova and by MC was 0.678 (<italic>p</italic> = 0.384), where the disagreement was related to codable Q-wave and their scores.</p>
<sec id="sec9-1741826711426091"><title>Prognosis of new ECG MI for CHD death and total mortality</title>
<p>New incident ECG MI categories were strong predictors for CHD death and all-cause mortality (<xref ref-type="table" rid="table3-1741826711426091">Tables 3</xref> and <xref ref-type="table" rid="table4-1741826711426091">4</xref>). Incident ECG MI by MC/Nova criteria had at least a 5.6 times higher [hazard ratio (HR) 6.81, 95% confidence interval (CI) 3.49–13.3 for Nova, and HR 5.66, 95% CI 2.70–11.9 for MC] in the multivariate models adjusted for demographic and clinical variables and ECG-LVH. Incident ECG MI by MC/Nova criteria doubled the risk for total mortality in all models (<xref ref-type="table" rid="table4-1741826711426091">Table 4</xref>).
<table-wrap id="table3-1741826711426091" position="float"><label>Table 3.</label><caption><p>CHD death by serial change for the Novacode (Nova) and the Minnesota Code (MC) during first scheduled follow-up visit to an average 17-year follow up (<italic>n</italic>/<italic>N</italic> = 280/12,477)</p></caption>
<graphic alternate-form-of="table3-1741826711426091" xlink:href="10.1177_1741826711426091-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>Event rates (<italic>n</italic>/<italic>N</italic>, %)</th>
<th>Univariate HR (95% CI)</th>
<th>Multivariate HR (95% CI)</th></tr></thead>
<tbody align="left">
<tr>
<td colspan="4">Nova serial change</td></tr>
<tr>
<td> I-Nova-5.1 to 5.4</td>
<td>13/54 (24)</td>
<td>11.8 (6.76–20.7)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td>
<td>6.81 (3.49–13.3)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td></tr>
<tr>
<td> I-Nova-5.5 to 5.6</td>
<td>17/217 (8)</td>
<td>3.99 (2.44–6.52)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td>
<td>2.32 (1.31–4.08)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">b</xref></sup></td></tr>
<tr>
<td> I-Nova-5.7</td>
<td>12/228 (5)</td>
<td>2.68 (1.50–4.78)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td>
<td>1.88 (0.96–3.69)</td></tr>
<tr>
<td> I-Nova-5.0</td>
<td>238/11,978 (2)</td>
<td>ref</td>
<td>ref</td></tr>
<tr>
<td colspan="4"> Q/ST-T</td></tr>
<tr>
<td>  Change</td>
<td>42/499 (8)</td>
<td>4.26 (3.07–5.92)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td>
<td>2.68 (1.83–3.91)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td></tr>
<tr>
<td>  No-change</td>
<td>238/11,978 (2)</td>
<td/>
<td/></tr>
<tr>
<td colspan="4">Combined MC serial change</td></tr>
<tr>
<td> I-MC-C.1 to C.4</td>
<td>11/49 (22)</td>
<td>11.4 (6.23–21.0)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td>
<td>5.66 (2.70–11.9)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td></tr>
<tr>
<td> I-MC-C.5 to C.6</td>
<td>40/552 (7)</td>
<td>4.06 (2.89–5.70)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td>
<td>2.55 (1.69–3.84)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td></tr>
<tr>
<td> I-MC-C.7</td>
<td>24/416 (6)</td>
<td>3.16 (2.07–4.83)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td>
<td>2.55 (1.61–4.03)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td></tr>
<tr>
<td> I-MC-C.0</td>
<td>205/11,460 (2)</td>
<td>ref</td>
<td>ref</td></tr>
<tr>
<td colspan="4"> Q/ST-T</td></tr>
<tr>
<td>  Change</td>
<td>75/1017 (7)</td>
<td>4.08 (3.13–5.31)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td>
<td>2.75 (2.01–3.75)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711426091">a</xref></sup></td></tr>
<tr>
<td>  No-change</td>
<td>205/11,460 (2)</td>
<td/>
<td/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1741826711426091"><p>See <xref ref-type="table" rid="table1-1741826711426091">Table 1</xref> for serial change criteria. <italic>n</italic> = number of events; <italic>N</italic> = number in that category of ECG MI, or each I-MC-C and I-Nova-5 codes. Multivariate hazard ratios (HR) adjusted for key demographic and clinical variables of age, gender, race, education, smoking status, alcohol use, diabetes, hypertension, cancer, body mass index, systolic blood pressure, white blood cell count, baseline glucose, insulin, fibrinogen, high-density lipoprotein, low-density lipoprotein, uric acid, creatinine, geographic regions, and left ventricular hypertrophy by Cornell voltage or MC 3.1 by MC/Nova. <sup>a</sup><italic>p</italic> &lt; 0.001; <sup>b</sup><italic>p</italic> &lt; 0.01.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table4-1741826711426091" position="float"><label>Table 4.</label><caption><p>Total mortality by serial change for Novacode (Nova) and Minnesota Code (MC) during first scheduled follow-up visit to an average of 17-year follow up (<italic>n</italic>/<italic>N</italic> = 2119/12,477)</p></caption>
<graphic alternate-form-of="table4-1741826711426091" xlink:href="10.1177_1741826711426091-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>Event rates (<italic>n</italic>/<italic>N</italic>, %)</th>
<th>Univariate HR (95% CI)</th>
<th>Multivariate HR (95% CI)</th></tr></thead>
<tbody align="left">
<tr>
<td colspan="4">Nova serial change</td></tr>
<tr>
<td> I-Nova-5.1 to 5.4</td>
<td>27/54 (50)</td>
<td>3.03 (2.07–4.43)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td>
<td>2.07 (1.31–3.27)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">b</xref></sup></td></tr>
<tr>
<td> I-Nova-5.5 to 5.6</td>
<td>83/217 (38)</td>
<td>2.38 (1.91–2.96)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td>
<td>1.47 (1.13–1.91)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">b</xref></sup></td></tr>
<tr>
<td> I-Nova-5.7</td>
<td>71/228 (31)</td>
<td>1.94 (1.53–2.46)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td>
<td>1.59 (1.23–2.05)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td></tr>
<tr>
<td> I-Nova-5.0</td>
<td>1938/11,978 (16)</td>
<td>ref</td>
<td>ref</td></tr>
<tr>
<td colspan="4"> Q/ST-T</td></tr>
<tr>
<td>  Change</td>
<td>181/499 (36)</td>
<td>2.25 (1.93–2.62)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td>
<td>1.58 (1.33–1.88)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td></tr>
<tr>
<td>  No change</td>
<td>1938/11,978 (16)</td>
<td/>
<td/></tr>
<tr>
<td colspan="4">Combined MC serial change</td></tr>
<tr>
<td> I-MC-C.1 to C.4</td>
<td>24/49 (49)</td>
<td>2.83 (1.89–4.24)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td>
<td>2.16 (1.38–3.27)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td></tr>
<tr>
<td> I-MC-C.5 to C.6</td>
<td>185/552 (34)</td>
<td>2.13 (1.84–2.48)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td>
<td>1.56 (1.31–1.87)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td></tr>
<tr>
<td> I-MC-C.7</td>
<td>104/416 (25)</td>
<td>1.56 (1.28–1.90)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td>
<td>1.28 (1.04–1.58)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">b</xref></sup></td></tr>
<tr>
<td> I-MC-C.0</td>
<td>1806/11,460 (16)</td>
<td>ref</td>
<td>ref</td></tr>
<tr>
<td colspan="4"> Q/ST-T</td></tr>
<tr>
<td>  Change</td>
<td>313/1017 (31)</td>
<td>1.93 (1.71–2.18)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td>
<td>1.47 (1.29–1.69)<sup><xref ref-type="table-fn" rid="table-fn4-1741826711426091">a</xref></sup></td></tr>
<tr>
<td>  No change</td>
<td>1806/11,460 (16)</td>
<td/>
<td/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1741826711426091"><p>See <xref ref-type="table" rid="table1-1741826711426091">Table 1</xref> for serial change criteria. <italic>n</italic> = number of events; <italic>N</italic> = number in that category of ECG MI, or each I-MC-C and I-Nova-5 codes. Multivariate hazard ratios (HR) adjusted for key demographic and clinical variables of age, gender, race, education, smoking status, alcohol use, diabetes, hypertension, cancer, body mass index, systolic blood pressure, white blood cell count, baseline glucose, insulin, fibrinogen, high-density lipoprotein, low-density lipoprotein, uric acid, creatinine, geographic regions, and left ventricular hypertrophy by Cornell voltage or MC 3.1 by MC/Nova. <sup>a</sup><italic>p</italic> &lt; 0.001; <sup>b</sup><italic>p</italic> &lt; 0.01.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec10-1741826711426091"><title>Isolated incident ECG ischaemia independently predicting CHD death and total mortality</title>
<p>Compared with incident ECG MI, major evolution of ST-T change alone was also a strong predictor for CHD death and total mortality (<xref ref-type="table" rid="table3-1741826711426091">Tables 3</xref> and <xref ref-type="table" rid="table4-1741826711426091">4</xref>). There was a 2–4-times increased risk for CHD death (HR 2.32, 95% CI 1.31–4.08 for I-Nova-5.5/5.6; and HR 2.55, 95% CI 1.69–⊟3.84 for I-MC-C.5/C.6). There was about 50% increased risk for total mortality by I-MC-C.5/C.6 or I-Nova-5.5/5.6 in the multivariate model. In summary, any new Q/ST-T serial change has ≥168% increased risk for CHD death and ≥47% increase risk for total mortality by either Nova or MC serial classification compared with no new Q/ST-T change group.</p>
<p>There was an interaction between the diagnosis of a clinical MI by the diagnostic committee and the appearance of a serial ECG MI or major Q/ST-T evolution at the first follow-up visit. ECG evolving new MI or major Q/ST-T with diagnostic clinic CHD MI (Supplementary <xref ref-type="table" rid="table3-1741826711426091">Tables 3</xref> and <xref ref-type="table" rid="table4-1741826711426091">4</xref>) increased the risk of CHD death by 7.5 times (HR 8.57, 95% CI 5.04–14.6) and doubled risk for total mortality (HR 2.29, 95% CI 1.61–3.24) (Supplementary Table 5). Noteworthy, evolving ECG major Q/ST-T by MC or Nova was also predictive of CHD and total mortality regardless of having adjudicated clinical MI at the same period or not. Evolving major Q/ST-T change in the absence of adjudicated clinical MI at first follow-up visit increased by 119% the risk for CHD death and indicated a 54% increased risk for total mortality as great as that for a clinic adjudicated MI without major serial ECG change (a 35% increase in risk).</p>
</sec>
</sec>
<sec id="sec11-1741826711426091" sec-type="discussion"><title>Discussion</title>
<p>Cardiovascular disease is a major cause of death and disability worldwide<sup><xref ref-type="bibr" rid="bibr15-1741826711426091">15</xref></sup> with the ECG contributing independent diagnostic and prognostic information.<sup><xref ref-type="bibr" rid="bibr16-1741826711426091">16</xref>–<xref ref-type="bibr" rid="bibr21-1741826711426091">21</xref></sup> Serial change classification for incident MI/ischaemia by MC or Nova has played an important role in numerous clinical trials and epidemiological studies.<sup><xref ref-type="bibr" rid="bibr5-1741826711426091">5</xref>–<xref ref-type="bibr" rid="bibr11-1741826711426091">11</xref>,<xref ref-type="bibr" rid="bibr21-1741826711426091">21</xref></sup> Coding by either Nova or MC has been well suited for incorporation in computer analysis programs as well as by visual review.</p>
<p>This is the first study to evaluate and compare the predictive power of serial change criteria by these two ECG classification systems. The relative strength of the two systems for prediction of the separate endpoints of CHD death and total mortality varied slightly.</p>
<p>Evolving Q-wave or ST-T as evidence of an incident MI or ischaemic event has been demonstrated previously in publications that have related ECG serial change to CHD death and total mortality. including the Multiple Risk Factor Intervention Trial (MRFIT)<sup><xref ref-type="bibr" rid="bibr6-1741826711426091">6</xref></sup> and the Framingham study.<sup><xref ref-type="bibr" rid="bibr21-1741826711426091">21</xref></sup> New incident ECG MI (with a major evolving Q-wave or evolving minor Q-wave plus evolving ST-T change) had a four-times higher related risk for coronary mortality in the MRFIT. The present study showed that new incident ECG MI increased by five times the risk for CHD death compared with those without any evolving Q/ST-T and doubled the risk for total mortality.</p>
<p>In the present study, 95% (523/552) of MC evolving ST categories were documented as ST-T1, ST-T3, and ST-T7 (major T-wave inversion to major T-wave inversion with 100% increase) and showed similar or higher risks than in MRFIT. The adjusted relative risks for CHD death in the present study were HRs 4.13, 1.82, and 3.31, respectively; and 2.29, 1.30, and 1.75 for total mortality. The combined code for all of isolated evolving ST-T categories had a HR 2.55 by MC, and 2.32 by Nova for CHD death. According this study, the Minnesota Code serial changes include more patients without apparent loss of specificity.</p>
<sec id="sec12-1741826711426091"><title>Study strengths and limitations</title>
<p>We focused only on electronic ECG data. Also, the serial change was between the baseline examination and the first follow-up exam that did not occur until 3 years later, so that it did not test those changes that might have occurred and regressed in the first 2 years of the study. The strength of the study is the large community-based population, long-term follow up, standardized ECG recording, and adjudicated outcomes.</p>
</sec>
</sec>
<sec id="sec13-1741826711426091" sec-type="conclusions"><title>Conclusions</title>
<p>ECG serial change criteria by both MC and Nova are equally valuable classification systems for detection of incident MI/ischaemia in clinical trials and epidemiological studies. Any incident ECG MI or isolated major evolving ST-T changes by Nova or MC are independent predictors for fatal cardiac events and all-cause mortality.</p>
</sec>
</body>
<back>
<sec id="sec14-1741826711426091"><title>Funding</title>
<p>The ARIC study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute (contract numbers HHSN268201100005C‐12 C).</p>
</sec>
<sec id="sec15-1741826711426091"><title>Conflict of interest</title>
<p>The authors declare they have no potential conflicts of interests.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The authors thank the staff and participants of the ARIC study for their important contributions.</p></ack>
<ref-list>
<title>References</title>
<ref id="bibr1-1741826711426091"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>GS</given-names></name><name><surname>Macfarlane</surname><given-names>P</given-names></name><name><surname>Wellens</surname><given-names>H</given-names></name><name><surname>Josephson</surname><given-names>M</given-names></name><name><surname>Gorgels</surname><given-names>A</given-names></name><name><surname>Mirvis</surname><given-names>DM</given-names></name><etal/></person-group>. <article-title>American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society. ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram part VI: acute ischemia/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology</article-title>. <source>J Am Coll Cardiol</source> <year>2009</year>; <volume>53</volume>(<issue>11</issue>): <fpage>1003</fpage>–<lpage>1011</lpage>.</citation></ref>
<ref id="bibr2-1741826711426091"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Ambrosioni</surname><given-names>E</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Brotons</surname><given-names>C</given-names></name><name><surname>Cifkova</surname><given-names>R</given-names></name><name><surname>Dallongeville</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2003</year>; <volume>10</volume>(<issue>4</issue>): <fpage>S1</fpage>–<lpage>S10</lpage>.</citation></ref>
<ref id="bibr3-1741826711426091"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luepker</surname><given-names>RV</given-names></name><name><surname>Apple</surname><given-names>FS</given-names></name><name><surname>Christenson</surname><given-names>RH</given-names></name><name><surname>Crow</surname><given-names>RS</given-names></name><name><surname>Fortmann</surname><given-names>SP</given-names></name><name><surname>Goff</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Case definitions for acute coronary heart disease in epidemiology and clinical research studies</article-title>. <source>Circulation</source> <year>2003</year>; <volume>108</volume>(<issue>20</issue>): <fpage>2543</fpage>–<lpage>2549</lpage>.</citation></ref>
<ref id="bibr4-1741826711426091"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>White</surname><given-names>HD</given-names></name></person-group>. <article-title>on behalf of the joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction: Universal definition of myocardial infarction</article-title>. <source>Circulation</source> <year>2007</year>; <volume>116</volume>(<issue>22</issue>): <fpage>2634</fpage><fpage>.</fpage>–<lpage>2654</lpage>.</citation></ref>
<ref id="bibr5-1741826711426091"><label>5</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Prineas</surname><given-names>RJ</given-names></name><name><surname>Crow</surname><given-names>R</given-names></name><name><surname>Blackburn</surname><given-names>H</given-names></name></person-group>. <source>The Minnesota Code manual of electrocardiographic findings</source>, <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>John Wright-PSG</publisher-name>, <year>1982</year>; <fpage>203</fpage>–<lpage>229</lpage>.</citation></ref>
<ref id="bibr6-1741826711426091"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crow</surname><given-names>RS</given-names></name><name><surname>Prineas</surname><given-names>RJ</given-names></name><name><surname>Hannan</surname><given-names>PJ</given-names></name><name><surname>Blackburn</surname><given-names>H</given-names></name></person-group>. <article-title>Prognostic associations of Minnesota Code serial electrocardiographic change classification with coronary heart disease mortality in the Multiple Risk Factor Intervention Trial</article-title>. <source>Am J Cardiol</source> <year>1997</year>; <volume>80</volume>(<issue>2</issue>): <fpage>138</fpage>–<lpage>144</lpage>.</citation></ref>
<ref id="bibr7-1741826711426091"><label>7</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Prineas</surname><given-names>RJ</given-names></name><name><surname>Crow</surname><given-names>RS</given-names></name><name><surname>Zhang</surname><given-names>ZM</given-names></name></person-group>. <source>The Minnesota Code manual of electrocardiographic findings</source>, <edition>2nd ed</edition>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer-London</publisher-name>, <year>2010</year>; <fpage>226</fpage>–<lpage>324</lpage>. <comment> [including measurement and comparison with the Novacode]</comment>.</citation></ref>
<ref id="bibr8-1741826711426091"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rautaharju</surname><given-names>PM</given-names></name><name><surname>Calhoun</surname><given-names>HP</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name></person-group>. <article-title>Novacode serial ECG classification system for clinical trials and epidemiological studies</article-title>. <source>J Electrocardiol</source> <year>1992</year>; <volume>24</volume>(<issue>S</issue>): <fpage>179</fpage>–<lpage>187</lpage>.</citation></ref>
<ref id="bibr9-1741826711426091"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rautaharju</surname><given-names>PM</given-names></name><name><surname>Park</surname><given-names>LP</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name><name><surname>Rautaharju</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>ZM</given-names></name></person-group>. <article-title>The Novacode criteria for classification of ECG abnormalities and their clinically significant progression and regression</article-title>. <source>J Electrocardiol</source> <year>1998</year>; <volume>31</volume>(<issue>3</issue>): <fpage>157</fpage>–<lpage>187</lpage>.</citation></ref>
<ref id="bibr10-1741826711426091"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>ZM</given-names></name><name><surname>Prineas</surname><given-names>RJ</given-names></name><name><surname>Eaton</surname><given-names>CB</given-names></name></person-group>. <article-title>Evaluation and comparison of the Minnesota Code and Novacode for electrocardiographic Q-ST-wave abnormalities for the independent prediction of incident coronary heart disease and total mortality (from the Women’s Health Initiative)</article-title>. <source>Am J Cardiol</source> <year>2010</year>; <volume>106</volume>(<issue>1</issue>): <fpage>18</fpage>–<lpage>25</lpage>.</citation></ref>
<ref id="bibr11-1741826711426091"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>ZM</given-names></name><name><surname>Prineas</surname><given-names>RJ</given-names></name><name><surname>Case</surname><given-names>D</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Burke</surname><given-names>GL</given-names></name></person-group>. <collab>for the Cardiovascular Health Study Research Group</collab>. <article-title>Gender differences between the Minnesota Code and Novacode electrocardiographic prognostication of coronary heart in the Cardiovascular Health Study</article-title>. <source>Am J Cardiol</source> <year>2011</year>; <volume>107</volume>(<issue>6</issue>): <fpage>817</fpage>–<lpage>820</lpage>.</citation></ref>
<ref id="bibr12-1741826711426091"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>ARIC Investigators</surname></name></person-group>. <article-title>The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives</article-title>. <source>Am J Epidemiol</source> <year>1989</year>; <volume>129</volume>(<issue>4</issue>): <fpage>687</fpage>–<lpage>702</lpage>.</citation></ref>
<ref id="bibr13-1741826711426091"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></name><name><surname>Howard</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>C-H</given-names></name><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>Rosamond</surname><given-names>WD</given-names></name><name><surname>Cooper</surname><given-names>LW</given-names></name><etal/></person-group>. <article-title>Trends in severity of hospitalized myocardial infarction: the Atherosclerosis Risk in Communities (ARIC) Study, 1987⊟1994</article-title>. <source>Am Heart J</source> <year>2000</year>; <volume>139</volume>(<issue>5</issue>): <fpage>874</fpage>–<lpage>880</lpage>.</citation></ref>
<ref id="bibr14-1741826711426091"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>AD</given-names></name><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>Chambless</surname><given-names>LE</given-names></name><name><surname>Sharret</surname><given-names>AR</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Conwill</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Community surveillance of coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) Study: methods and initial two years’ experience</article-title>. <source>J Clin Epidemiol</source> <year>1996</year>; <volume>49</volume>(<issue>2</issue>): <fpage>223</fpage>–<lpage>233</lpage>.</citation></ref>
<ref id="bibr15-1741826711426091"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roger</surname><given-names>VL</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Lloyd-Jones</surname><given-names>DM</given-names></name><name><surname>Adams</surname><given-names>RJ</given-names></name><name><surname>Berry</surname><given-names>JD</given-names></name><name><surname>Brown</surname><given-names>TM</given-names></name><etal/></person-group><collab>American Heart Association Statistics Committee and Stroke Statistics Subcommittee</collab>. <article-title>Heart disease and stroke statistics – 2011 update: a report from the American Heart Association</article-title>. <source>Circulation</source> <year>2011</year>; <volume>123</volume>(<issue>4</issue>): <fpage>e18</fpage>–<lpage>e209</lpage>.</citation></ref>
<ref id="bibr16-1741826711426091"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Prineas</surname><given-names>RJ</given-names></name><name><surname>Arnold</surname><given-names>AM</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Furberg</surname><given-names>CD</given-names></name><name><surname>Robbins</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Prevalence, prognosis, and implication of isolated minor nonspecific ST-segment and T-wave abnormalities in older adults: Cardiovascular Health Study</article-title>. <source>Circulation</source> <year>2008</year>; <volume>118</volume>(<issue>25</issue>): <fpage>2790</fpage>–<lpage>2796</lpage>.</citation></ref>
<ref id="bibr17-1741826711426091"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rautaharju</surname><given-names>PM</given-names></name><name><surname>Grace</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>JC</given-names></name><name><surname>Marino-Larsen</surname><given-names>EK</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Furberg</surname><given-names>CD</given-names></name><etal/></person-group>. <article-title>Comparison of mortality risk for electrocardiographic abnormalities in men and women with and without coronary heart disease (from the Cardiovascular Health Study)</article-title>. <source>Am J Cardiol</source> <year>2006</year>; <volume>97</volume>(<issue>3</issue>): <fpage>309</fpage>–<lpage>315</lpage>.</citation></ref>
<ref id="bibr18-1741826711426091"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>ZM</given-names></name><name><surname>Prineas</surname><given-names>RJ</given-names></name><name><surname>Case</surname><given-names>D</given-names></name><name><surname>Soliman</surname><given-names>EZ</given-names></name><name><surname>Rautaharju PM for ARIC Research Group</surname></name></person-group>. <article-title>Comparison of the prognostic significance of the electrocardiographic QRS/T angles in predicting incident coronary heart disease and total mortality (from the atherosclerosis risk in communities study)</article-title>. <source>Am J Cardiol</source> <year>2007</year>; <volume>100</volume>(<issue>5</issue>): <fpage>844</fpage>–<lpage>849</lpage>.</citation></ref>
<ref id="bibr19-1741826711426091"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rautaharju</surname><given-names>PM</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Larson</surname><given-names>JC</given-names></name><name><surname>LaCroix</surname><given-names>A</given-names></name></person-group>. <article-title>Electrocardiographic abnormalities that predict coronary heart disease events and mortality in postmenopausal women. The Women’s Health Initiative</article-title>. <source>Circulation</source> <year>2006</year>; <volume>113</volume>(<issue>4</issue>): <fpage>473</fpage>–<lpage>480</lpage>.</citation></ref>
<ref id="bibr20-1741826711426091"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prineas</surname><given-names>RJ</given-names></name><name><surname>Grandits</surname><given-names>G</given-names></name><name><surname>Rautaharju</surname><given-names>PM</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>ZM</given-names></name><name><surname>Crow</surname><given-names>RS</given-names></name></person-group>. <article-title>Long-term prognostic significance of isolated minor electrocardiographic T-Wave abnormalities in middle aged men free of clinic cardiovascular disease. The Multiple Risk Factor Study (MRFIT)</article-title>. <source>Am J Cardiol</source> <year>2002</year>; <volume>90</volume>(<issue>12</issue>): <fpage>1391</fpage>–<lpage>1395</lpage>.</citation></ref>
<ref id="bibr21-1741826711426091"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kannel</surname><given-names>WB</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>McGee</surname><given-names>DL</given-names></name><name><surname>Degatano</surname><given-names>LS</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name></person-group>. <article-title>Nonspecific electrocardiographic abnormality as a predictor of coronary heart disease: the Framingham Study</article-title>. <source>Am Heart J</source> <year>1987</year>; <volume>113</volume>(<issue>2</issue>): <fpage>370</fpage>–<lpage>376</lpage>.</citation></ref>
</ref-list>
</back>
</article>